Newsroom

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF. “Welcome to our Weekly Report Issue 70. Let me start with a major breakthrough for FF’s robotics business in the Middle East. On August 28, FF officially launched its robotics business in the Middle East and completed the sale...

LOS ANGELES--(BUSINESS WIRE)--LHX Investors Have Opportunity to Join L3Harris Technologies, Inc. Fraud Investigation with SBS Law...

LOS ANGELES--(BUSINESS WIRE)--CLMT Investors Have Opportunity to Join Calumet, Inc. Fraud Investigation with SBS Law...

ABU DHABI, Emirados Árabes Unidos--(BUSINESS WIRE)--Sob o patrocínio de Sua Alteza Sheikh Hamdan bin Zayed Al Nahyan, Representante do Governante na Região de Al Dhafra e Presidente do Clube de Falcoeiros dos Emirados, o quinto leilão realizado como parte da 23ª edição da Exposição Internacional de Caça e Hipismo de Abu Dhabi (ADIHEX) 2026 atraiu um público notável, culminando na venda de um falcão Qarmousha Pure Ultra White por AED 1,5 milhão (USD 408.000). A venda representa o preço mais alto...

SINGAPORE & TEL-AVIV, Israel & NEW YORK--(BUSINESS WIRE)--Sygnia, the foremost global cyber readiness and response team, released the findings of their investigation into ongoing activity by a China-nexus threat actor, targeting key infrastructure that routes, authenticates, connects, and manages high-value environments. Tracked by Sygnia as ‘Fire Ant’, the adversary leveraged novel attack tools and methods to target Cisco IOS XR routers and turn them into operational platforms that suppress ev...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. SHASTA-3 and SHASTA-4 met their primary and all prespecified secondary endpoints and demonstrated deep and durable reductions in triglycerides (TG),...

CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--L3Harris Technologies (NYSE: LHX) has contributed key elements to NASA’s successfully launched Nancy Grace Roman Space Telescope, an observatory designed to map the universe. The milestone also marks the culmination of more than a decade of engineering, innovation and collaboration between L3Harris and NASA’s Goddard Space Flight Center. L3Harris provided the 2.4-meter Optical Telescope Assembly (OTA) for NASA, which serves as Roman’s eye. The company also...

FORT COLLINS, Colo.--(BUSINESS WIRE)--Angel Armor launches the RISE® Plate Carrier, a purpose-built tactical armor platform designed for SWAT teams, tactical law enforcement personnel and high-risk response environments. The new carrier officially debuts at the NTOA Conference in Booth 515, where it will be a primary product focus for Angel Armor throughout the show.The RISE® Plate Carrier was developed around a challenge tactical operators have faced for years: getting the coverage they need wi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data ex...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzamitide) for the diagnosis of cardiac amyloidosis.1 The pivotal study met its primary endpoints in the assessment of sensitivity and specificity for the diagnosis of cardiac amyloidosis b...